Prevalence And Associated Factors Of Chronic Kidney Disease Among Relatives Of Hemodialysis Patients in Saudi Arabia

Chronic kidney disease (CKD) is a serious health issue in the Kingdom of Saudi Arabia (KSA). In KSA, there are currently over 20,000 patients on dialysis and 9,810 patients undergoing follow-up after kidney transplantation.1 The combined prevalence of renal replacement therapy in Saudi Arabia is estimated at 294.3 per million population.1

In Saudi Arabia, the age-standardized prevalence of CKD (stages 1–2, stage 3, stage 4, and stage 5, not including renal replacement therapy) is estimated at 9,892 per 100,000, which is higher than the estimates for Western Europe (5,446 per 100,000) and North America (7,919 per 100,000).2 Based on the National Health and Nutrition Examination Survey (NHANES), the prevalence of CKD in adults in the United States of America (US) is 11.7%.3 We found only a single study of the prevalence of CKD among the young Saudi population (mean age of 37.4±11.3 years).4 This study estimated CKD prevalence within this segment of the Saudi population at 5.7% using the modification of diet in renal disease (MDRD)-3 equation and 5.3% using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.

According to relevant studies,cistanche is a traditional Chinese herb that has been used for centuries to treat various diseases. It has been scientifically proven to possess anti-inflammatory, anti-aging, and antioxidant properties. Studies have shown that cistanche is beneficial for patients suffering from kidney disease. The active ingredients of cistanche are known to reduce inflammation, improve kidney function and restore impaired kidney cells. Thus, integrating cistanche within a kidney disease treatment plan can offer great benefits to patients in managing their condition. Cistanche helps to reduce proteinuria, lowers BUN and creatinine levels, and decreases the risk of further kidney damage. In addition, cistanche also helps reduce cholesterol and triglyceride levels which can be dangerous to patients suffering from kidney disease.

Click To Where Can I Buy Cistanche

Ask for more: david.deng@wecistanche.com  WhatApp:86 13632399501

Cistanche's antioxidant and anti-aging properties help to protect the kidneys from oxidation and damage caused by free radicals. This improves kidney health and reduces the risks of developing complications. Cistanche also helps to boost the immune system, which is essential in fighting off kidney infections and promoting kidney health. By combining traditional Chinese herbal medicine and modern western medicine, those suffering from kidney disease can have a more comprehensive approach to treating the condition and improving their quality of life. Cistanche should be used as part of a treatment plan but is not to be used as an alternative to conventional medical treatments.

Individuals at higher risk for the development of CKD include those with a strong family history of CKD.5, S1-S3 Studies in the US have confirmed the high prevalence of CKD among relatives of end-stage kidney disease (ESKD) patients with 14% of screened relatives having GFR < 60 ml/min/1.73m2 (20-24). First or second-degree relatives of patients with ESKD are 2 to 3 times more likely to develop ESKD and are more likely to be obese and to have undetected hypertension.6, S1, S4, S5 Thus, individuals with a family history of CKD are a high-risk group as are hypertensive, diabetics, and those over 65 years of age.S3

RESULTS

Demographic and Clinical Characteristics

The characteristics of the 5177 relatives (26% of the total invited) are shown in Table 1. Relatives presented for CKD screening from all regions of KSA: 23.2%, 20.7%, 28.9 %, and 27.2% from the central, eastern, western, and southern regions. The most common relatives screened were offspring (63.7%). The mean age of the screened relatives was 34.3±14.3 years, and the mean BMI was 29.6±11.8 kg/m2.

In the index patients (Table S1), most had a primary diagnosis for their CKD of DM (45.5%), followed by those of unknown etiology (20.2%) and hypertension (19.8%). Inherited kidney diseases contributed only 0.12% of the total.

Prevalence of Chronic Kidney Disease and Associated Factors

Mean serum creatinine was 80.9±26.4 mmol/l, and the mean eGFR was 96.4± 22.6 ml/min/1.73m2 (Table 2). Of all relatives screened, 54.6% had eGFR > 90 ml/min/1.73m2, indicative of healthy kidney status, 39.6% had eGFR < 90 ml/min/1.73m2, and 5.8% had eGFR of less than 60 ml/min/1.73m2. Of the relatives with eGFR, between 60 and 90 ml/min/1.73m2,8% had proteinuria. Thus, the prevalence of CKD was 13.8% (5.8% eGFR < 60 ml/min/1.73m2+8% with proteinuria and eGFR 60 – 90 ml/min/1.73m2). There were 68% in CKD stages 0 – 1 and 32% in stages 2 – 5. The prevalence

Relatives with BMI > 30 kg/m2, indicative of being overweight, constituted 39.8% of the total. An even higher fraction (66.2%) had a BMI > 25 kg/m2, indicative of obesity. Mean SBP was 123.5±18.1 mm Hg and diastolic blood pressure was 77.6 ±111.2 mm Hg. Although only 14.3% reported a history of hypertension, we found that 28.1% had systolic hypertension and 8.6% had diastolic hypertension, suggesting that undiagnosed hypertension was common.

We compared the frequency of hypertension, obesity, and potentially uncontrolled DM in the relatives with CKD and those without CKD (Table S2). Systolic hypertension was more common in the relatives with CKD (35.9%) compared to those without (29.2%). Of the relative's studies, > 30% had a BMI of  > 30 kg/m2 and 40.5 % on anti-diabetic medication had glycosuria, which could indicate uncontrolled DM. 

To evaluate risk factors that were associated with more severe kidney disease, we compared the characteristics of the relatives with stages 0 – 1 disease to those with stages 2 – 5 disease (Table 3). The relatives with stages 0-1 were significantly younger (31.3 ± 12.8 years) than those in the later stages (40.9 ± 15 years) and had a higher prevalence of a history of hypertension or DM and a BMI > 25 (P Using logistic regression analysis, we found that ¼ 0.0001).

Using logistic regression analysis, we found that ¼ 0.0001). relatives with stages 2 – 5 had the following independently associated risk factors: age, region, proteinuria, and systolic hypertension (Table 4).

Among this subset of the relatives screened, 860 (17.1%) said that they are on medication with 5.1% taking antidiabetic medications, 2.7% on antihypertensive medications, and 1.3% on nonsteroidal anti-inflammatory drugs (NSAIDs). The patients in the Southern region had the lowest rate of medication use, including antidiabetic medication and NSAIDs (Table S3).

DISCUSSION

In this study, we screened more than 5000 first-degree relatives of Saudi patients on hemodialysis. The subjects consisted of equal proportions from the four geographical regions of Saudi Arabia and had an equal distribution between males and females. The respondents constituted 26% of the total number of relatives approached. The prevalence of CKD among the relatives screened was 13.8%, which is 2.6 times that reported in the Saudi population for similar age groups.4 Other reports have also shown a higher prevalence of CKD among hemodialysis patient families that in the general population from different parts of the world.5,6, S1 The relatives screened in our study tended to be young (mean age 34.3 years). It is conceivable that as they age, the prevalence of CKD among them will be substantially higher. Another limitation of our study related to capturing proteinuria on a urinalysis, which is subject to inaccuracies due to high or low urine specific gravity.

It was noteworthy that the prevalence of CKD among the screened relatives of patients from the southern region was between 2 to 4-fold higher than the prevalence in other regions. Although the relatives from the southern region had a significantly higher prevalence of CKD, the prevalence of diabetes among the relatives and their index cases was the lowest among the four regions. The opposite characteristics were observed in the relatives from the eastern region, which had the highest prevalence of DM and the lowest prevalence of CKD. These geographic differences suggested that the family history of CKD is caused by something other than familial diabetes. Consanguineous marriages are common within Saudi families (57%), but there is no evidence that is more common in the South.7 Thus, the geographic data suggested a possible autosomal dominant inherited kidney disease was prevalent in the South.

In the Saudi population of the same age bracket as our screened relatives, the prevalence of diabetes is 12.1%,3 which was almost half the prevalence of the relatives reporting a history of diabetes (23.4%). On the day of screening, only 9.5% of the cohort had glycosuria. This low proportion compared to the self-reported history information could be at least partially due to the 5.1% who reported taking antidiabetic medication. Alternatively, the self-reporting regarding the history of DM could be inaccurate. We found no positive association between the prevalence of DM and CKD in the relatives among the different regions. Indeed, in the eastern and southern regions, these conditions were negatively correlated.

Among relatives with CKD, the prevalence of systolic hypertension was significantly higher than among the relatives without CKD (p ¼ 0.03). This is consistent with previous reports.5 On the day of screening, 28.1% of the relatives had systolic hypertension, even though only 14.3% reported a history of hypertension. Thus, our result suggested a frequency of undiagnosed hypertension of 13.8%. There was diastolic hypertension in 8.6%. Our findings are consistent with another study from Saudi Arabia, which reported 15.2% of adult Saudis were hypertensive, and 57.8% were unaware of this diagnosis.S6

We found that in the screened relatives, the prevalence of obesity (BMI of > 30kg/m2 ) was 39.8%, which is higher than reported for the general Saudi population (28.7%).S7 A higher prevalence of obesity was also observed in the relatives with stages 2 – 5 CKD (70.9 %) compared with those in stages 0 – 1 (63.2%). This is in keeping with previous reports showing that obesity among incident dialysis patients was independently associated with a family history of CKD. This raises the possibility of adiposity-related genes being a cause of CKD.S4